《别有用心的妻子》,《无憾》坎贝奇在线听,《禁忌5》无删减

盧米西他濱

NMR下載 COA and HPLC MSDS下載
names：
Lumicitabine
CAS號：
1445385-02-3
MDL Number： No data available
MF(分子式)： C18H25ClFN3O6 MW(分子量)： 433.86
EINECS:No data available Reaxys Number:No data available
Pubchem ID:89658382 Brand:BIOFOUNT

盧米西他濱(1445385-02-3,Lumicitabine)是呼吸道合胞病毒（RSV）聚合酶的抑制劑。Lumicitabine可轉化為血漿循環型ALS-8112，然后轉化為宿主細胞內的5'-活性三磷酸核苷（NTP）形式。

貨品編碼	規格	純度	價格 (￥)	現價(￥)	特價(￥)	庫存描述	數量	總計 (￥)
YZM000870-5mg	5mg	99%	￥ 3543.00	￥ 3543.00		2-3天	- +	￥ 0.00
YZM000870-1mg	1mg	99%	￥ 1462.00	￥ 1462.00		2-3天	- +	￥ 0.00

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產品

*產品名稱：

CAS號：

產品編號：

需求描述：

請準確填寫您的聯系方式，以便為您提供最好的服務。

*公司名稱：

*電子郵箱：

聯系人：

*電話：

*驗證碼：

詢價

中文別名	盧米西他濱(1445385-02-3,Lumicitabine);ALS-8176;ALS-008176
英文別名	Lumicitabine(1445385-02-3);ALS-8176;ALS-008176
CAS號	1445385-02-3
Inchi	InChI=1S/C18H25ClFN3O6/c1-9(2)15(24)27-8-18(7-19)13(28-16(25)10(3)4)12(20)14(29-18)23-6-5-11(21)22-17(23)26/h5-6,9-10,12-14H,7-8H2,1-4H3,(H2,21,22,26)/t12-,13+,14-,18-/m1/s1
InchiKey	MJVKYGMNSQJLIN-KYZVSKTDSA-N
分子式 Formula	C18H25ClFN3O6
分子量 Molecular Weight	433.86
溶解度Solubility	生物體外In Vitro:DMSO溶解度≥ 50 mg/mL(115.24 mM)*"≥" means soluble可溶, but saturation unknown溶解度未知.
性狀	白色至灰白色固體粉末
儲藏條件 Storage conditions	-20°C 3 years年 4°C 2 years年 / 溶液中:-80°C 6 months月 -20°C 1 month月

盧米西他濱(1445385-02-3,Lumicitabine)實驗注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質及有害物質產生，必要時實驗操作需要手套箱內完成以免對實驗人員造成傷害
3.實驗后產生的廢棄物需分類存儲，并交于專業生物廢氣物處理公司處理，以免造成環境污染

Lumicitabine(1445385-02-3) Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tag:盧米西他濱(1445385-02-3,Lumicitabine),Lumicitabine試劑,Lumicitabine抑制劑,Lumicitabine的雜質,Lumicitabine的純度,Lumicitabine的MSDS,Lumicitabine的作用,Lumicitabine的外觀,Lumicitabine的使用,Lumicitabine的合成,Lumicitabine的生產

產品說明	盧米西他濱(1445385-02-3,Lumicitabine)是呼吸道合胞病毒（RSV）聚合酶的抑制劑。
Introduction	Lumicitabine (1445385-02-3,盧米西他濱) is an inhibitor of the respiratory syncytial virus (RSV) polymerase.
Application1
Application2
Application3

Lumicitabine is under investigation in clinical trial NCT03010059 (A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations).

警示圖
危險性	warning
危險性警示	Not available
安全聲明	H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對身體有害
安全防護	P264處理后徹底清洗+P280戴防護手套/穿防護服/戴防護眼罩/戴防護面具+P305如果進入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續沖洗+P337如果眼睛刺激持續+P2393獲得醫療建議/護理
備注	實驗過程中防止吸入、食入，做好安全防護

Potent in vitro activity of β-D-4'-chloromethyl-2'-deoxy-2'-fluorocytidine against Nipah virus PMID 31935422; Antiviral research 2020 03; 175( ):104712

Synthesis of 4'-Substituted-2'-Deoxy-2'-α-Fluoro Nucleoside Analogs as Potential Antiviral Agents PMID 32168734; Molecules (Basel, Switzerland) 2020 Mar; 25(6):

Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humans PMID 30376079; The Journal of antimicrobial chemothe

Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference PMID 30974127; Antiviral research 2019 07; 167(?):45-67 (Review Article)

Antiviral treatment of severe non-influenza respiratory virus infection PMID 29095723; Current opinion in infectious diseases 2017 Dec; 30(6):573-578 (Review Article)

Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children
Introduction:The REGAL (RSV Evidence – A Geographical Archive of the Literature) series has provided a comprehensive review of the published evidence in the field of respiratory syncytial virus (RSV) in Western countries over the last 20 years. This seventh and final publication covers the past, present and future approaches to the prevention and treatment of RSV infection among infants and children.
Methods:A systematic review was undertaken of publications between January 1, 1995 and December 31, 2017 across PubMed, Embase and The Cochrane Library. Studies reporting data on the effectiveness and tolerability of prophylactic and therapeutic agents for RSV infection were included. Study quality and strength of evidence (SOE) were graded using recognized criteria. A further nonsystematic search of the published literature and Clinicaltrials.gov on antiviral therapies and RSV vaccines currently in development was also undertaken.

Results:The systematic review identified 1441 studies of which 161 were included. Management of RSV remains centered around prophylaxis with the monoclonal antibody palivizumab, which has proven effective in reducing RSV hospitalization (RSVH) in preterm infants < 36 weeks’ gestational age (72% reduction), children with bronchopulmonary dysplasia (65% reduction), and infants with hemodynamically significant congenital heart disease (53% reduction) (high SOE). Palivizumab has also shown to be effective in reducing recurrent wheezing following RSVH (high SOE). Treatment of RSV with ribavirin has conflicting success (moderate SOE). Antibodies with increased potency and extended half-life are currently entering phase 3 trials. There are approximately 15 RSV vaccines in clinical development targeting the infant directly or indirectly via the mother.

Conclusion:Palivizumab remains the only product licensed for RSV prophylaxis, and only available for high-risk infants. For the general population, there are several promising vaccines and monoclonal antibodies in various stages of clinical development, with the aim to significantly reduce the global healthcare impact of this common viral infection.

對不起，暫無產品評價！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開